Last updated: February 25, 2026
What is NDC 61269-0981?
NDC 61269-0981 corresponds to Ruxolitinib (brand name Jakafi), a JAK1/JAK2 inhibitor approved for treatment of myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and refractory graft-versus-host disease.
Market Overview
Market Size and Demand
- Global Myeloproliferative Neoplasms (MPNs) Market: Expected to reach $2.8 billion by 2026, CAGR of approximately 8.5% (Research and Markets, 2022).
- Jakafi's Share: Dominates the MPN treatment segment with an estimated 75% market share.
- Patient Population (U.S.): Around 50,000 patients diagnosed with myelofibrosis and polycythemia vera, with roughly 70% receiving pharmacotherapy (American Society of Hematology, 2021).
Competitive Landscape
- Key Competitors: Fedratinib (Inrebic), fedratinib's market share is growing post-approval but remains smaller.
- Pipeline Products: Several JAK inhibitors in phase 2/3 trials, including momelotinib and pacritinib, could impact Jakafi sales in the next 3–5 years.
Price Point and Revenue Data
Current Price and Sales
- Average Wholesale Price (AWP): Approximately $147,000 per year per patient in the U.S. (Red Book, 2023).
- Estimated U.S. Sales (2022): $2.3 billion, driven by market penetration in MPNs and expanding indications.
Price Components
- Per-Unit Cost: Ruxolitinib is dosed twice daily, with typical regimens requiring 20–50 mg per dose.
- Pricing Strategy: Premium pricing reflecting the drug's efficacy, unmet needs in refractory cases, and limited competition.
Price Projections (Next 3–5 Years)
| Year |
Estimated U.S. Sales ($ billions) |
Average Price per Patient ($) |
Market Penetration |
Key Factors Affecting Price |
| 2023 |
2.3 |
147,000 |
70% |
Stable demand, pipeline threats remain minimal, increased off-label use. |
| 2024 |
2.45 |
150,000 |
72% |
Price adjustments due to inflation, increased manufacturing costs. |
| 2025 |
2.6 |
153,000 |
74% |
Competition from approved alternatives, potential biosimilar entry in other settings. |
| 2026 |
2.8 |
155,000 |
75% |
Market saturation, patent protections limit immediate biosimilar impact. |
Note: Price increases are conservative estimates based on inflation and increased manufacturing/logistics costs.
Impact of Biosimilar and Regulatory Changes
- Biosimilar Entry: Limited for JAK inhibitors in the U.S. due to patent protections and complex biosimilar pathways.
- Patent Expiry: Estimated between 2028–2030 for core formulations.
- Regulatory Approvals: New indications or combination therapies could expand sales but may pressure pricing.
Key Takeaways
- Market Dominance: Jakafi maintains a leading position in MPNs with high sales and pricing power.
- Pricing Outlook: Slight increases projected through 2026, stabilized by patent protections and limited biosimilar competition.
- Competitive Risks: Emerging therapies and biosimilar developments could impact long-term pricing and market share post-2028.
FAQs
1. What factors influence Ruxolitinib's market share?
Demand is driven by its efficacy in treating certain blood cancers, limited competition, and FDA-approved indications. Patent protection and regulatory exclusivity sustain its market dominance.
2. How might biosimilar competition affect prices?
Biosimilar entry can reduce prices by 20–40%, depending on market adoption and reimbursement policies. However, biosimilar approvals for JAK inhibitors are limited, delaying impact.
3. Are there upcoming patent expirations for Ruxolitinib?
Patent protection generally lasts until 2028–2030, after which biosimilars could enter the market and pressure prices.
4. What is the potential for off-label use affecting sales and pricing?
Off-label use for related indications may increase demand marginally but could also lead to pricing negotiations with payers and insurers.
5. How does pipeline activity influence future market projections?
Future approvals of competing JAK inhibitors or novel therapies could erode Jakafi's market share, impacting revenue and pricing strategies.
References
- American Society of Hematology. (2021). Myeloproliferative neoplasms. Retrieved from https://www.hematology.org
- Research and Markets. (2022). Global Myeloproliferative Neoplasms Market Forecast. Retrieved from https://www.researchandmarkets.com
- Red Book. (2023). Drug Pricing and Market Data. Wolters Kluwer.
